Evidence map›Paper›PMID 24461786›Full record

ArticleThe Journal of pediatrics2014

Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants.

Nicole R Dobson, Ravi M Patel, P Brian Smith, Devon R Kuehn, Jennifer Clark, Shilpa Vyas-Read, Amy Herring, Matthew M Laughon, David Carlton, Carl E Hunt

Erratum issued 3 registry-linked trialsAbstract readComparative StudyEvaluation Study
In one paragraph

Article in The Journal of pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 74 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 5 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02677584 nacompletednot on this mapstarted 2015, after this paper: background citation

Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity

TypeinterventionalSponsorMansoura University Children HospitalRan2015 to 2018Enrolled180ConditionsApneaArmsProphylactic caffeine citrate, Therapeutic caffeine citrate
NCT03086473 phase4unknown statusnot on this mapstarted 2017, after this paper: background citation

A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates

TypeinterventionalSponsorJennifer ShepherdRan2017 to 2022Enrolled24ConditionsBPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, IntubationArmsCaffeine Citrate, Placebo (Normal Saline)
NCT05295784 phase1withdrawnnot on this mapstarted 2024, after this paper: background citation

Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia

TypeinterventionalSponsorUniversity of ArkansasRan2024 to 2024Enrolled0ConditionsAcute Kidney Injury, Hypoxic-Ischemic Encephalopathy, CaffeineArmsCaffeine citrate
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 5 syntheses or guidelines pooled it, 176 citations in OpenAlex.

  1. Administration time of caffeine in preterm infants: systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Variation of caffeine use in late preterm infants in U.S. NICUs over time: A 12-year cohort study.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Article
  12. Caffeine for the prevention of acute kidney injury in neonates: a systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. What is the Role of Caffeine in the Management of Preterm Infants?Current treatment options in pediatrics · 2025
    Review
  19. Article
  20. Observational

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Nicole R Dobson *Department of Pediatrics, Uniformed Services University of Health Sciences, Bethesda, MD.
Ravi M Patel *Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.
P Brian SmithDuke Clinical Research Institute, Durham, NC.
Devon R KuehnWomack Army Medical Center, Fort Bragg, NC.
Jennifer ClarkUniversity of North Carolina School of Public Health, Chapel Hill, NC.
Shilpa Vyas-ReadEmory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.
Amy HerringUniversity of North Carolina School of Public Health, Chapel Hill, NC.
Matthew M LaughonDepartment of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
David CarltonEmory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA.
Carl E HuntDepartment of Pediatrics, Uniformed Services University of Health Sciences, Bethesda, MD.
Emory University · USUniversity of North Carolina at Chapel Hill · USUniversity of Health SciencesDuke University · USWomack Army Medical Center · US

Funding

Duke CTSA (Composite)UL1TR001117 · NCATS · DUKE UNIVERSITY · PI BOULWARE, LEIGH E, LI, JENNIFER S · 2013 to 2017
$41.3M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalKL2TR000455 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$2.9M
Antimicrobial pharmacokinetics and outcomes in vulnerable infantsK23HD068497 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAUGHON, MATTHEW · 2011 to 2015
$586k
PHARMACOKINETICS OF ANTIMICROBIAL AGENTS IN HIGH RISK INFANTSK23HD060040 · NICHD · DUKE UNIVERSITY · PI SMITH, PHILLIP BRIAN · 2009 to 2012
$445k
ASPE HHS 1R18AE000028-01NCATS NIH HHS KL2 TR000455NCATS NIH HHS KL2TR000455NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NCATS NIH HHS UL1 TR001117NCATS NIH HHS UL1TR001117NHLBI NIH HHS 1K23HL092225-01NICHD NIH HHS HHSN267200700051CNICHD NIH HHS HHSN275201000003INICHD NIH HHS K23 HD060040NICHD NIH HHS K23 HD068497NICHD NIH HHS L40 HD069892
6 · The paper itself

Abstract

objectiveTo examine the effect of early initiation of caffeine therapy on neonatal outcomes and characterize the use of caffeine therapy in very low birth weight (VLBW) infants. STUDY

designWe analyzed a cohort of 62 056 VLBW infants discharged between 1997 and 2010 who received caffeine therapy. We compared outcomes in infants receiving early caffeine therapy (initial dose before 3 days of life) and those receiving late caffeine therapy (initial dose at or after 3 days of life) through propensity scoring using baseline and early clinical variables. The primary outcome was the association between the timing of caffeine initiation and the incidence of bronchopulmonary dysplasia (BPD) or death.

resultsWe propensity score-matched 29 070 VLBW infants at a 1:1. Of infants receiving early caffeine therapy, 3681 (27.6%) died or developed BPD, compared with 4591 infants (34.0%) receiving late caffeine therapy (OR, 0.74; 99% CI, 0.69-0.80). Infants receiving early caffeine had a lower incidence of BPD (23.1% vs 30.7%; OR, 0.68; 95% CI, 0.63-0.73) and a higher incidence of death (4.5% vs 3.7%; OR, 1.23; 95% CI, 1.05-1.43). Infants receiving early caffeine therapy had less treatment of patent ductus arteriosus (OR, 0.60; 95% CI, 0.55-0.65) and a shorter duration of mechanical ventilation (mean difference, 6 days; P < .001).

conclusionEarly caffeine initiation is associated with a decreased incidence of BPD. Randomized trials are needed to determine the efficacy and safety of early caffeine prophylaxis in VLBW infants.

Indexed as

Infant MortalityInfant, Very Low Birth WeightBronchopulmonary DysplasiaCaffeineCentral Nervous System StimulantsDrug Administration ScheduleDuctus Arteriosus, PatentFemaleHumansIncidenceInfant, NewbornInfant, PrematureIntensive Care, NeonatalMalePractice Patterns, Physicians'Propensity ScoreCaffeineCentral Nervous System Stimulants

Identifiers

PMID24461786
PMCPMC3992195
OpenAlexW2131997206

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.